Radius Health Publishes Investor Presentation Outlining Company's Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium

Urges stockholders to vote "FOR " Radius' highly qualified, independent director nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE proxy card BOSTON, July 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (NASDAQ:RDUS ) today published a detailed investor presentation available at: https://ir.radiuspharm.com/events-and-presentations/ . The document discusses the Company's progress since 2020 and also outlines the comprehensive strategic review process conducted by the Radius Board of Directors, which resulted in its unanimous approval of the Company's acquisition by Gurnet Point Capital and Patient Square Capital at a significant premium. Stockholders are urged to vote "FOR" all three of the Company's highly qualified, independent nominees on the BLUE proxy card at its upcoming Annual Meeting of Stockholders, which will be held online on July 26, 2022. YOUR VOTE IS IMPORTANT VOTE "FOR" RADIUS' THREE NOMINEES ON THE  BLUE  PROXY CARD TODAY 509 Madison Avenue New York, NY 10022 Email: RDUS@info.morrowsodali.com Call toll-free at (800) 662-5200 (in North America) or +1 (203) 658-9400 (outside of North America) About Radius Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, neuro- orphan diseases, and oncology. Radius' lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple neuro-endocrine, neurodevelopmental, or neuropsychiatric disease areas, initially targeting Prader-Willi syndrome, Angelman syndrome, and infantile spasms. Forward-Looking Statements This communication contains forward-looking statements, including the ability of the parties to complete the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement") by and among ... Full story available on Benzinga.com